Atreleuton (ABT-761) 是一种选择性的、可逆的、口服可生物利用的 5-脂加氧酶 (5-LO) 抑制剂。Atreleuton (ABT-761) 有效选择性的抑制白三烯形成。
CAS：154355-76-7
分子式：C16H15FN2O2S
分子量：318.37
纯度：98%
存储：Store at -20°C

Background:

Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. 5-LO[1]

[1]. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc. [2]. Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. [3]. Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73.